Manhattan Associates Shares Gain on Boost to Guidance, 2Q Earnings Beat
Dow Jones2026/07/28 22:45By Elias Schisgall
Shares of Manhattan Associates rose after the company lifted its full-year guidance and reported second-quarter revenue growth ahead of Wall Street expectations.
Shares were up 8.8% at $183.00 after Tuesday's bell, after closing up 5.6% at $168.17. At close, the stock was down 3% year to date.
The maker of supply-chain and industry software said it now expects full-year revenue to grow between 7% and 8% to between $1.16 billion and $1.17 billion. It forecast adjusted earnings between $5.44 and $5.50 a share.
The company had previously forecast 6% to 7% revenue growth and adjusted earnings between $5.29 and $5.37 a share. Analysts polled by FactSet are expecting adjusted earnings of $5.37 a share on $1.15 billion in revenue.
Manhattan Associates on Tuesday reported a second-quarter profit of $50.4 million, or 85 cents a share, compared with a profit of $56.8 million, or 93 cents a share, a year earlier.
Stripping out certain one-time items, adjusted earnings were $1.39 a share. Analysts were expecting $1.32 a share.
Revenue rose to $297.8 million from $272.4 million. Analysts had been expecting $287.7 million in revenue.
Services revenue grew to $133 million from $128.9 million, while cloud subscriptions rose to $126.7 million from $100.4 million.
The company ended the quarter with $2.47 billion in remaining performance obligations.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
July 28, 2026 18:45 ET (22:45 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst: This 2026 XRP Price Prediction Way Well Go Into the History Books
Bitcoin Red Team Claims Blockstream Ignored Warnings Before Hack
Bitcoin's Weirdest Trader Yet? Fly Brain Makes a Profit
Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness - Heard on the Street -- WSJ